Anlotinib as maintenance therapy for children with high-risk rhabdomyosarcoma
Part of Cancer clinical trials.
This trial tests a daily oral medication (anlotinib) as a maintenance therapy to help prevent rhabdomyosarcoma from coming back in children who have already finished their main treatment and are in complete remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be between 5 and 18 years old.
- Diagnosed with intermediate- or high-risk rhabdomyosarcoma that has certain high-risk features (like age over 10, poor genetics, or tumor that couldn't be fully removed).
- Finished first treatment and scans show no sign of remaining cancer (complete remission).
- Have recovered from side effects of previous cancer treatments, and lab tests (like blood counts, liver, kidney) are in a safe range.
- No uncontrolled high blood pressure, serious heart problems, bleeding issues, or recent major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, toripalimab and anlotinib, as maintenance therapy after initial treatment for extensive stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from growing for as long as possible.
This trial tests if the drug anlotinib can safely and effectively treat recurrent craniopharyngioma, a type of brain tumor. It is for patients whose tumor has come back or grown after previous treatment.
This trial compares two treatment combinations—liposomal doxorubicin plus irinotecan versus a different chemotherapy plan—in children and teens whose rhabdomyosarcoma came back or did not respond. It aims to see which option works better and is safer for children who have had prior cancer treatment.
This trial tests whether adding all-trans retinoic acid to a standard chemotherapy regimen (VAC) can improve outcomes for people with intermediate-to-high-risk rhabdomyosarcoma. It is for those who have not had prior cancer drug treatment and have adequate organ function.
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or not responded to treatment. The goal is to see if this combination can shrink or control the tumor.
Hear when a new Maintenance Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.